X4 Pharmaceuticals
Clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Launch date
Employees
Market cap
€109m
Enterprise valuation
€26m (Public information from Sep 2024)
Share price
$0.708 XFOR
Cambridge Massachusetts (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 3.0m | - | - | - | 6.3m | 44.1m | 102m |
% growth | - | - | - | - | - | 597 % | 130 % |
EBITDA | (59.9m) | (65.6m) | (88.6m) | (102m) | - | - | - |
% EBITDA margin | (1996 %) | - | - | - | - | - | - |
Profit | (62.1m) | (88.7m) | (93.9m) | (101m) | (42.6m) | (111m) | (76.5m) |
% profit margin | (2071 %) | - | - | - | (675 %) | (253 %) | (75 %) |
EV / revenue | 34.9x | - | - | - | 18.7x | 2.7x | 1.2x |
EV / EBITDA | -1.8x | -1.0x | -1.4x | -1.4x | - | - | - |
R&D budget | 41.9m | 50.6m | 61.1m | 72.0m | - | - | - |
R&D % of revenue | 1398 % | - | - | - | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | N/A | $15.0m | Early VC |
$37.5m | Series A | ||
* | N/A | $7.5m Valuation: $188m | Early VC |
* | N/A | $7.5m | Debt |
N/A | Series A | ||
$27.0m | Series B | ||
N/A | N/A | IPO | |
* | N/A | $85.8m | Post IPO Equity |
* | N/A | $65.0m | Post IPO Equity |
* | N/A | $65.0m | Post IPO Equity |
* | $115m | Post IPO Debt | |
* | $20.0m | Post IPO Debt | |
Total Funding | €79.1m |
Recent News about X4 Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.